98% relapse-free Soliris is reimbursed for NMOSD in Korea
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.10 05:50:25
가나다라
0
98% of patients treated with Soliris remained relapse-free in clinical trial…treatment effect sustained through 144 weeks of treatment
Relapse rates for NMOSD are high, but patient access to the drug remains a challenge due to new drug reimbursement criteria
▲Ho Jin Kim, Head of Department of Neurology & Division of Clinical Research, National Cancer Center
A new treatment option has been introduced for patients with neuromyelitis optica spectrum disorder (NMOSD), a disease that has over a 90% relapse rate. Soliris became fully reimbursable for NMOSD last month, recording a 98% relapse-free rate. However, there are concerns that the stringent reimbursement requirements for Soliris may reduce patient access to the treatment. On May 7, AstraZeneca Korea held a press conference at the Conrad Hotel in Seoul to celebrate the reimbursement of Soliris for NMOSD in Korea.
Soliris is a C5 complement inhibitor developed by AstraZeneca. It binds to the C5 protein and prevents the activation of a complement terminal complex, which has been shown to be
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)